Literature DB >> 1719023

Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors.

H M Cheng1, Y T Foong, C K Sam, U Prasad, J Dillner.   

Abstract

The entire amino acid sequence of the unique region of the EBNA 1 protein was synthesized as a set of 41 20-residue peptides with an overlap of 10 amino acids. The peptides were tested in the enzyme-linked immunosorbent assay for reactivity with immunoglobulin A (IgA) and IgG in sera from 50 patients with nasopharyngeal carcinoma (NPC) as compared with 36 serum samples from healthy Epstein-Barr virus (EBV)-seropositive donors and 5 serum samples from EBV-negative donors. The most immunoreactive peptide for both IgA and IgG binding was localized to the glycine-alanine repeat domain of the antigen. In the unique regions, 16 immunoreactive peptides were found. Of these, four were reactive with IgG but not IgA and three peptides were reactive with IgA but not IgG in NPC sera. In addition, several IgA and IgG epitopes on the carboxy-terminal region were specifically reactive with NPC sera, but unreactive with sera from healthy EBV-positive donors. The results suggest that EBV serology specific for individual epitopes may provide additional useful information not available by conventional serology with whole antigens or the EBNA complex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719023      PMCID: PMC270294          DOI: 10.1128/jcm.29.10.2180-2186.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma.

Authors:  Y T Foong; H M Cheng; C K Sam; J Dillner; W Hinderer; U Prasad
Journal:  Int J Cancer       Date:  1990-06-15       Impact factor: 7.396

2.  Antibodies against the large subunit of the EBV-encoded ribonucleotide reductase in patients with nasopharyngeal carcinoma.

Authors:  M Ginsburg
Journal:  Int J Cancer       Date:  1990-06-15       Impact factor: 7.396

3.  Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames.

Authors:  J Dillner; L Dillner; G Utter; C Eklund; A Rotola; S Costa; D DiLuca
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

4.  Identification and characterization of a cellular protein that cross-reacts with the Epstein-Barr virus nuclear antigen.

Authors:  J Luka; T Kreofsky; G R Pearson; K Hennessy; E Kieff
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

5.  Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis.

Authors:  A Linde; B Kallin; J Dillner; J Andersson; L Jägdahl; A Lindvall; B Wahren
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

6.  Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli.

Authors:  E Littler; W Newman; J R Arrand
Journal:  Int J Cancer       Date:  1990-06-15       Impact factor: 7.396

7.  Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection.

Authors:  R S Smith; R B Naso; J Rosen; A Whalley; Y L Hom; K Hoey; C J Kennedy; J A McCutchan; S A Spector; D D Richman
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

8.  One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain.

Authors:  K Hennessy; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  Repeat array in Epstein-Barr virus DNA is related to cell DNA sequences interspersed on human chromosomes.

Authors:  M Heller; A Henderson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

10.  Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen.

Authors:  J Dillner; L Sternås; B Kallin; H Alexander; B Ehlin-Henriksson; H Jörnvall; G Klein; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

View more
  11 in total

1.  Evaluation of antibodies against different Epstein-Barr virus nuclear antigen 1 peptides in diagnosis of nasopharyngeal carcinoma.

Authors:  Ai-Di Gu; Hao-Yuan Mo; Jin-Xin Bei; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Yi-Xin Zeng
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

2.  Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.

Authors:  H M Cheng; Y T Foong; A J AbuSamah; J Dillner; C K Sam; U Prasad
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 3.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

4.  Challenges in the management of nasopharyngeal carcinoma: a review.

Authors:  Baharudin Abdullah; Azila Alias; Shahid Hassan
Journal:  Malays J Med Sci       Date:  2009-10

5.  Tumor microenvironment contributes to Epstein-Barr virus anti-nuclear antigen-1 antibody production in nasopharyngeal carcinoma.

Authors:  Ping Ai; Zhiping Li; Yong Jiang; Changping Song; Lin Zhang; Huaizhong Hu; Tao Wang
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

6.  Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients.

Authors:  R Tedeschi; J Dillner; P De Paoli
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

7.  Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.

Authors:  Rosamaria Tedeschi; Elisa Pin; Debora Martorelli; Ettore Bidoli; Alessia Marus; Chiara Pratesi; Maria Teresa Bortolin; Stefania Zanussi; Emanuela Vaccher; Riccardo Dolcetti; Paolo De Paoli
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

8.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Authors:  Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Cell Proteomics       Date:  2016-02-01       Impact factor: 5.911

9.  Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis.

Authors:  K H Rand; H Houck; N D Denslow; K M Heilman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

10.  EBV-Associated Cancer and Autoimmunity: Searching for Therapies.

Authors:  Giovanni Capone; Candida Fasano; Guglielmo Lucchese; Michele Calabrò; Darja Kanduc
Journal:  Vaccines (Basel)       Date:  2015-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.